Intralesional Triamcinolone for Flares of Hidradenitis Suppurativa: A Case Series

December 2016 in “ Journal of the American Academy of Dermatology ”

P. Theut Riis, Jurr Boer, Errol P. Prens, Ditte Marie Lindhardt Saunte, I.E. Deckers, Lennart Emtestam, Karin Sartorius, Gregor B. E. Jemec

intralesional triamcinolone hidradenitis suppurativa erythema edema suppuration lesion size pain scores intralesional corticosteroid injections inflammation triamcinolone HS corticosteroid injections

TLDR Intralesional triamcinolone effectively reduces pain and inflammation in hidradenitis suppurativa flares.

The study evaluated the effectiveness of intralesional triamcinolone (10 mg/mL) for managing acute flares in hidradenitis suppurativa (HS) through a prospective case series. Significant reductions in physician-assessed erythema, edema, suppuration, and lesion size were observed (all P < .0001). Patient-reported pain scores also significantly decreased after 1 day (from 5.5 to 2.3, P < .005) and from day 1 to day 2 (from 2.3 to 1.4, P < .002). Despite the small study size, open single-arm design, and short follow-up time, both physicians and patients perceived intralesional corticosteroid injections as beneficial for reducing pain and inflammation in HS flares.

View this study on secure.jbs.elsevierhealth.com →